Lobaplatin

Last updated
Lobaplatin
Lobaplatin.svg
Clinical data
Routes of
administration 		IV Bolus Injections or Infusion
Identifiers
  • 1,2-diammino-methy lcyclobutane-platinum (II) lactate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
Formula C9H18N2O3Pt
Molar mass 397.338 g·mol−1
Melting point 220 °C (428 °F)
Solubility in water 72.9 mg/mL (20 °C)

Lobaplatin is a platinum-based antineoplastic metallodrug approved exclusively in China for the treatment of small cell lung cancer, inoperable metastatic breast cancer and chronic myelogenous leukaemia. [1] The drug is a third-generation analogue of cisplatin, the first globally approved and widely used platinum-based anticancer drug.

Contents

Pharmacodynamics studies of lobaplatin found greater anticancer activity and lower toxicity than cisplatin and carboplatin, and showed activity against cisplatin-resistant cancer cells. [1] However, global approval of lobaplatin is restricted due to limited evidence of efficacy.

Structure

The structure of lobaplatin (1,2-diammino-methyl-cyclobutane-platinum (II) lactate) consists of a platinum(II) metal center coordinated to a bidentate amine ligand (1,2-bis(aminomethyl)cyclobutane) and a lactic acid leaving group. [2] Lobaplatin is administered intravenously by bolus injection or infusion and composed of an approximate 50/50 mixture of two diastereoisomers, R,R,S- and S,S,S-configurations. [3]

Mechanism of action

The mechanism of antineoplastic action for lobaplatin has not been studied in great detail. The results of current mechanistic studies suggest that lobaplatin is a DNA cross linking antineoplastic agent and has a similar platinum-induced cytotoxicity mechanism to other platin metallodrugs (i.e., cisplatin and oxaliplatin). [4]

Lobaplatin acts as a pro-drug, it is hydrolyzed in the body forming an active form that is able to interact with DNA. [5] Specifically, when lobaplatin is hydrolyzed the lactate ligand is protonated and dissociates as lactic acid, forming a charged and highly reactive platinum complex that coordinates with the N-donors of DNA bases and inhibits DNA synthesis. [6] In its reactive (active) form, the platinum metal center is able to form DNA-adducts through inter- and intra-strand cross-links with two adjacent guanine-guanine (GG) or two guanine-adenine (GA) bases, inducing apoptosis and inhibition of cell growth. [2] Lobaplatin has been shown to affect the expression of the c-myc gene, which is associated with apoptosis and cell proliferation. [7]

Toxicity and side effects

The toxicity of platinum-based drugs is highly dependent on how easily the leaving group(s) are hydrolyzed, leaving groups that easily dissociate are significantly more toxic than more stable leaving groups that don't easily disassociate. [3] Due to the good stability of the lactic acid leaving group, lobaplatin is more stable and therefore less toxic than first and second generation platinum-based drugs. [6]

The toxicity of lobaplatin is common across multiple clinical trials, 60 mg/m2 (body surface area) per 3–4 weeks is the maximum tolerated dose and the dose-limiting toxicity is thrombocytopenia. [2] Common side effects include agranulocytosis, thrombocytopenia, anaemia, leukopenia, nausea and vomiting. [3] [1]

History

Lobaplatin was first synthesized and developed by ASTA Pharma in Germany in 1990, under the research name D-19466. [8] Discontinued development of lobaplatin by ASTA Pharma lead to further development of the drug by Zentaris AG (AEterna Laboratories). [8] In 2003, Zentaris AG signed a contract with Hainan Tianwang International Pharmaceutical for the manufacturing and marketing of lobaplatin in China. [8] In 2010, lobaplatin was approved for clinical use in china, according to China Food and Drug Administration.

Related Research Articles

<span class="mw-page-title-main">Chemotherapy</span> Treatment of cancer using drugs that inhibit cell division or kill cells

Chemotherapy is the type of cancer treatment that uses one or more anti-cancer drugs in a standard regimen. Chemotherapy may be given with a curative intent, or it may aim only to prolong life or to reduce symptoms. Chemotherapy is one of the major categories of the medical discipline specifically devoted to pharmacotherapy for cancer, which is called medical oncology.

<span class="mw-page-title-main">Carboplatin</span> Medication used to treat cancer

Carboplatin, sold under the brand name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.

<span class="mw-page-title-main">Cisplatin</span> Chemical compound and pharmaceutical drug

Cisplatin is a chemical compound with formula cis-[Pt(NH3)2Cl2]. It is a coordination complex of platinum that is used as a chemotherapy medication used to treat a number of cancers. These include testicular cancer, ovarian cancer, cervical cancer, bladder cancer, head and neck cancer, esophageal cancer, lung cancer, mesothelioma, brain tumors and neuroblastoma. It is given by injection into a vein.

<span class="mw-page-title-main">Oxaliplatin</span> Pharmaceutical drug

Oxaliplatin, sold under the brand name Eloxatin among others, is a cancer medication used to treat colorectal cancer. It is given by injection into a vein.

<span class="mw-page-title-main">Busulfan</span> Chemical compound

Busulfan is a chemotherapy drug in use since 1959. It is a cell cycle non-specific alkylating antineoplastic agent, in the class of alkyl sulfonates. Its chemical designation is 1,4-butanediol dimethanesulfonate.

<span class="mw-page-title-main">Tirapazamine</span> Chemical compound

Tirapazamine is an experimental anticancer drug that is activated to a toxic radical only at very low levels of oxygen (hypoxia). Such levels are common in human solid tumors, a phenomenon known as tumor hypoxia. Thus, tirapazamine is activated to its toxic form preferentially in the hypoxic areas of solid tumors. Cells in these regions are resistant to killing by radiotherapy and most anticancer drugs. Thus the combination of tirapazamine with conventional anticancer treatments is particularly effective. As of 2006, tirapazamine is undergoing phase III testing in patients with head and neck cancer and gynecological cancer, and similar trials are being undertaken for other solid tumor types.

<span class="mw-page-title-main">Altretamine</span> Chemical compound

Altretamine, also called hexamethylmelamine, is an antineoplastic agent. It was approved by the U.S. FDA in 1990.

Triplatin tetranitrate is a platinum-based cytotoxic drug that underwent clinical trials for the treatment of human cancer. The drug acts by forming adducts with cellular DNA, preventing DNA transcription and replication, thereby inducing apoptosis. Other platinum-containing anticancer drugs include cisplatin, carboplatin, and oxaliplatin.

<span class="mw-page-title-main">Alkylating antineoplastic agent</span> Pharmaceutical drugs

An alkylating antineoplastic agent is an alkylating agent used in cancer treatment that attaches an alkyl group (CnH2n+1) to DNA.

<span class="mw-page-title-main">Satraplatin</span> Chemical compound

Satraplatin is a platinum-based antineoplastic agent that was under investigation as a treatment of patients with advanced prostate cancer who have failed previous chemotherapy. It has not yet received approval from the U.S. Food and Drug Administration. First mentioned in the medical literature in 1993, satraplatin is the first orally active platinum-based chemotherapeutic drug; other available platinum analogues—cisplatin, carboplatin, and oxaliplatin—must be given intravenously.

<span class="mw-page-title-main">Nedaplatin</span> Chemical compound

Nedaplatin is a platinum-based antineoplastic drug which is used for cancer chemotherapy. The complex consists of two ammine ligands and the dianion derived from glycolic acid.

<span class="mw-page-title-main">Semustine</span> Chemical compound

Semustine is an alkylating nitrosourea compound used in chemotherapy treatment of various types of tumours. Due to its lipophilic property, semustine can cross the blood-brain barrier for the chemotherapy of brain tumours, where it interferes with DNA replication in the rapidly-dividing tumour cells. Semustine, just as lomustine, is administered orally. Evidence has been found that treatment with semustine can cause acute leukaemia as a delayed effect in very rare cases.

Lipoplatin is a nanoparticle of 110 nm average diameter composed of lipids and cisplatin. This new drug has successfully finished Phase I, Phase II, and Phase III human clinical trials. It has shown superiority to cisplatin in combination with paclitaxel as a chemotherapy regimen in non-small cell lung cancer (NSCLC) adenocarcinomas.

Platinum-based antineoplastic drugs are chemotherapeutic agents used to treat cancer. Their active moieties are coordination complexes of platinum. These drugs are used to treat almost half of people receiving chemotherapy for cancer. In this form of chemotherapy, commonly used drugs include cisplatin, oxaliplatin, and carboplatin, but several have been proposed or are under development. Addition of platinum-based chemotherapy drugs to chemoradiation in women with early cervical cancer seems to improve survival and reduce risk of recurrence.

Ruthenium anti-cancer drugs are coordination complexes of ruthenium complexes that have anticancer properties. They promise to provide alternatives to platinum-based drugs for anticancer therapy. No ruthenium anti-cancer drug has been commercialized.

Arabinopyranosyl-<i>N</i>-methyl-<i>N</i>-nitrosourea Chemical compound

Arabinopyranosyl-N-methyl-N-nitrosourea, also known as Aranose (Араноза) is a cytostatic anticancer chemotherapeutic drug of an alkylating type. Chemically it is a nitrosourea derivative. It was developed in the Soviet Union in the 1970s. It was claimed by its developers that its advantages over other nitrosoureas are a relatively low hematological toxicity and a wider therapeutic index, which allows for its outpatient administration.

<span class="mw-page-title-main">Crisnatol</span> Chemical compound

Crisnatol (BW-A770U) is an experimental anticancer agent known for its potential in inhibiting the growth of various solid tumors. Research has indicated that crisnatol acts as a DNA-intercalating agent, thereby disrupting the replication process in cancer cells. A Phase I clinical trial was conducted to assess its safety profile, pharmacokinetics, and potential efficacy in patients with solid malignancies. This study highlighted the drug’s ability to inhibit tumor growth, although associated toxicities were observed, necessitating further research to optimize its therapeutic window.

<span class="mw-page-title-main">Dicycloplatin</span> Chemical compound

Dicycloplatin is a chemotherapy medication used to treat a number of cancers which includes the non-small-cell lung carcinoma and prostate cancer.

<span class="mw-page-title-main">KP1019</span> Chemical compound

KP1019, or indazole trans-[tetrachlorobis(1H-indazole)ruthenate(III)], is one of four ruthenium anti-cancer drugs to enter into phase I clinical trials, the others being BOLD-100, NAMI-A and TLD-1433. Research into ruthenium-based drugs has provided novel alternatives for platinum-based chemotherapeutics such as Cisplatin and its derivatives. KP1019 is useful for metastatic tumors and cis-platin resistant tumors. It exhibits potent cytotoxicity against primary tumors, particularly in colorectal cancer.

RAPTA is a class of experimental cancer drugs. They consist of a central ruthenium(II) atom complexed to an arene group, chlorides, and 1,3,5-triaza-7-phosphaadamantane (PTA) forming an organoruthenium half-sandwich compound. Other related ruthenium anti-cancer drugs include NAMI-A, KP1019 and BOLD-100.

References

  1. 1 2 3 "Lobaplatin: D 19466". Drugs in R&D. 4 (6): 369–372. 2003. doi:10.2165/00126839-200304060-00008. PMID   14584968.
  2. 1 2 3 McKeage MJ (January 2001). "Lobaplatin: a new antitumour platinum drug". Expert Opinion on Investigational Drugs. 10 (1): 119–128. doi:10.1517/13543784.10.1.119. PMID   11116285. S2CID   23771556.
  3. 1 2 3 Wheate NJ, Walker S, Craig GE, Oun R (September 2010). "The status of platinum anticancer drugs in the clinic and in clinical trials". Dalton Transactions. 39 (35): 8113–8127. doi:10.1039/c0dt00292e. hdl: 2123/9269 . PMID   20593091.
  4. ↑ Boulikas T (2008-11-21). "Platinum Drugs". In Missailidis S, Pantos A, Bellis E, Christofis P (eds.). Anticancer Therapeutics, S. Missailidis (Ed.). Chichester, UK: John Wiley & Sons, Ltd. pp. 55–78. doi:10.1002/9780470697047.ch5. ISBN   978-0-470-69704-7.
  5. ↑ Saygin D, Tabib T, Bittar HE, Valenzi E, Sembrat J, Chan SY, et al. (October 2016). "Transcriptional profiling of lung cell populations in idiopathic pulmonary arterial hypertension". Pulmonary Circulation. 10 (1): 115–122. doi:10.1016/j.cplett.2016.10.004. PMC   7052475 . PMID   32166015.
  6. 1 2 "NCI Dictionaries: Lobaplatin". National Cancer Institute. U.S. Department of Health and Human Services. 2011-02-02. Retrieved 2022-10-09.
  7. ↑ Eliopoulos AG, Kerr DJ, Maurer HR, Hilgard P, Spandidos DA (June 1995). "Induction of the c-myc but not the cH-ras promoter by platinum compounds". Biochemical Pharmacology. 50 (1): 33–38. doi:10.1016/0006-2952(95)00085-e. PMID   7605342.
  8. 1 2 3 Voegeli R, Schumacher W, Engel J, Respondek J, Hilgard P (September 1990). "D-19466, a new cyclobutane-platinum complex with antitumor activity". Journal of Cancer Research and Clinical Oncology. 116 (5): 439–442. doi:10.1007/bf01612990. PMID   2229133. S2CID   9620899.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.